Pulsenmore Ltd.

What they do

Pulsenmore focuses on research, development, manufacture, marketing, and sale of innovative, non-invasive portable ultrasound solutions for home use. Its primary products are the Pulsenmore ES and the Pulsenmore FC, with a third solution, the Pulsenmore MC, in earlier developmental stages. The products target home scans in gynecology, as well as pulmonary, cardiology, and urology applications.

Revenue drivers

• Pulsenmore ES — One of two primary products; a portable ultrasound device for home use, though specific revenue contribution is not disclosed.
• Pulsenmore FC — The second primary product; a portable ultrasound device for home use, with no separate revenue breakdown provided.
• Pulsenmore MC — An additional portable ultrasound solution in earlier developmental stages; not yet commercialized and no revenue generated.

Recent performance

The filing does not provide specific financial results for the fiscal year ended December 31, 2025, other than noting that the company had 6,502,844 ordinary shares outstanding as of December 31, 2025 and March 15, 2026. The company effected a one-for-eight reverse split on December 28, 2025, and its ordinary shares began trading on the Nasdaq Capital Market on January 21, 2026. No revenue, net income, or cash flow figures are included in the provided excerpts.

Strategy

Pulsenmore is focused on developing and commercializing its non-invasive portable ultrasound solutions for home use. The company completed a reverse split and listed on Nasdaq in early 2026, which may improve access to capital and visibility. Its strategy includes advancing the Pulsenmore MC, which is in earlier developmental stages, and expanding applications beyond gynecology into pulmonary, cardiology, and urology.

Risks

• Early-stage commercialization — As an emerging medical device company, Pulsenmore may not have significant revenue and faces challenges in achieving regulatory approvals and market adoption.
• Regulatory and reimbursement — The company's products are subject to extensive regulation by health authorities, and obtaining reimbursement from payors may be difficult and time-consuming.
• Competition — The portable ultrasound market is competitive, with larger, established medical device companies potentially offering competing products.
• Dependence on key products — The company's future success depends on the successful commercialization of its Pulsenmore ES and FC products, and any delay or failure could harm its business.

Outlook

Management does not provide specific financial guidance in the excerpts. The company's recent Nasdaq listing and reverse split may position it for growth, but no forward-looking statements about revenue or profitability are included in the provided text.